Setting the Stage: Why Uveal Melanoma Requires a Different Clinical Mindset

In this segment, our panel establishes why uveal melanoma is a fundamentally different disease from cutaneous melanoma and why that distinction matters for every treatment decision that follows. You will hear why the low mutational burden of uveal melanoma makes it largely unresponsive to the checkpoint inhibitors that have transformed outcomes in skin melanoma, and what that means for patients who come to you having read about immunotherapy successes in other melanoma subtypes. The panel also addresses the liver as the central clinical challenge in metastatic uveal melanoma, discussing the biological reasons the disease favors hepatic spread and why controlling liver disease must be at the center of any treatment strategy from the moment of diagnosis.